Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Clinical trial NCT04851613 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04851613
- Sponsor
- Laekna Limited
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-18
- Primary completion
- 2026-10-30
- Enrollment
- 256
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.